[Prevalence of anti hepatitis C antibodies in patients with chronic renal failure receiving conservative therapy].
The prevalence of hepatitis C varies according to geographical areas and risk groups. Patients with terminal chronic renal failure (TCRF) under dialysis are an important risk group. In Peru, hepatitis C virus (HCV) infection rates in patients under hemo-dialysis reach 90%, and are associated with transfusions and time under dialysis as risk factors. Little is known about the prevalence of HCV in patients with TCRF receiving non dialysis therapy. The purpose of this study is to know the prevalence of HCV infection in these patients and to determine the risk factors. Prospective study, anti-hepatitis C (anti HCV) antibodies were assessed in patients with TCRF in non-dialysis conservative therapy at the Department of Nephrology of the Arzobispo Loayza Hospital. Ninety nine (99) patients were studied, 54.1% male and 45.8% female, with an average age of 56.6 + 17.9 years, with an average time of CRF diagnosis of 9.28 + 14.35 months. The most frequent cause of CRF was the unknown cause, followed by diabetes. A rate of anti HCV of 1.01% (1/99) was found. A low prevalence of antiHCV was found in the population studied. It was similar to the rates found in populations without CTRF.